COPD Treatment Landscape Expands, Yet Significant Gaps in Disease Control and Access Persist, According to Spherix Global Insights

Persistent access barriers leave many treatment candidates without advanced therapy as physicians look for stronger disease ...
Thorax

Targeting fatigue in COPD with chronic respiratory failure undergoing pulmonary rehabilitation: a multicentre, randomised, placebo-controlled trial of L-arginine/lipos…

Background Pulmonary rehabilitation (PR) is the cornerstone of non-pharmacological treatment for chronic obstructive ...
Express Pharma

AstraZeneca’s AZD6793 holds potential to expand oral COPD treatment options, says GlobalData

Congress 2026, AstraZeneca presented the design of the Phase IIb PRESTO trial, a large study set to evaluate whether AZD6793, ...